About
Gala holds a B.S. in Mathematics from Vanderbilt University and an M.B.A. from Columbia Business School. She worked in the energy industry in corporate finance and mergers and acquisitions, then at Eli Lilly from 2001 to 2006 and at Theravance from 2006, where she became Chief Financial Officer of Theravance Biopharma in December 2014. She was CFO of GRAIL in 2019, joined Jazz as CFO in March 2020, and became President and Chief Operating Officer in October 2023. She succeeded Bruce Cozadd, who had been CEO since 2012. Other biotech and pharmaceutical chief executives with pages on Whoo include Chris Viehbacher of Biogen and Leonard Schleifer of Regeneron.
Whoo compiled this page from public sources: Jazz 2026 proxy statement (SEC), Jazz Form 10-Q, September 2026 (SEC), Jazz Form 10-K, 2025 (SEC). It is not affiliated with or endorsed by Renee Gala. Are you Renee Gala? Claim this page, or write to [email protected] to correct or remove it. Last updated: 2026-11-18.
Want a page like this? Create yours from your résumé.
Experience
President and Chief Executive Officer — Jazz Pharmaceuticals
August 2025 – Present | Dublin, Ireland
- Also serves as a director
- Joined Theravance in 2006
President and Chief Operating Officer — Jazz Pharmaceuticals
October 2023
Executive Vice President and Chief Financial Officer — Jazz Pharmaceuticals
March 2020
Chief Financial Officer — GRAIL, Inc.
January – June 2019
Senior Vice President and Chief Financial Officer — Theravance Biopharma
December 2014 – January 2019
Treasury, sales and corporate development roles — Eli Lilly and Company
2001 – 2006